Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
复制标题
DOI：
10.1158/1078-0432.ccr-09-2175
复制
发表时间：
2010-02-15
影响因子：
11.5
通讯作者：
Escudier, Bernard J.
中科院分区：
文献类型：
--
作者：
Lassau, Nathalie;Koscielny, Serge;Escudier, Bernard J.
目的：确定动态超声造影（DCE-US）作为转移性肾癌患者接受舒尼替尼治疗的预后工具的效用，并确定与早期治疗反应相关的DCE-US参数。实验设计：38例患者接受50 mg/d舒尼替尼治疗，疗程4/2（治疗4周后停药2周）。两个周期后，使用实体瘤的应答评价标准将患者分为应答者或无应答者。治疗前和第15天分别进行DCE-US评估；计算7个DCE-US功能参数在第0天和第15天之间的变化，并比较反应者和无反应者。评估DCE-US参数与无病生存期（DFS）和总生存期（OS）的相关性。结果：基线和第15天DCE-US检查之间的比率与7个DCE-US参数中的5个参数的反应显着相关。两个DCE-US参数（峰值强度时间和冲洗斜率）与DFS显著相关；达到峰值强度的时间也与OS显著相关。结论：DCE-US是预测转移性肾细胞癌患者舒尼替尼早期疗效的有效工具。功能参数与经典评估（包括DFS和OS）之间存在显著相关性。临床癌症研究；16 (4);1216 - 25。(c) 2010年aacr。
Purpose: To determine the utility of dynamic contrast-enhanced ultrasonography (DCE-US) as a prognostic tool for metastatic renal cell carcinoma patients receiving sunitinib and to identify DCE-US parameters that correlate with early treatment response.Experimental Design: Thirty-eight patients received 50 mg/d sunitinib on schedule 4/2 (4 weeks on followed by 2 weeks off treatment). After two cycles, response evaluation criteria in solid tumors were used to classify patients as responders or nonresponders. DCE-US evaluations were done before treatment and at day 15; variations between days 0 and 15 were calculated for seven DCE-US functional parameters and were compared for responders and nonresponders. The correlation between DCE-US parameters and disease-free survival (DFS) and overall survival (OS) was assessed.Results: The ratio between DCE-US examinations at baseline and day 15 significantly correlated with response in five of the seven DCE-US parameters. Two DCE-US parameters (time to peak intensity and slope of the wash-in) were significantly associated with DFS; time to peak intensity was also significantly associated with OS.Conclusions: DCE-US is a useful tool for predicting the early efficacy of sunitinib in metastatic renal cell carcinoma patients. Robust correlations were observed between functional parameters and classic assessments, including DFS and OS. Clin Cancer Res; 16(4); 1216-25. (C) 2010 AACR.